头孢曲松联合大环内酯与单药治疗HIV/AIDS住院CAP患者:随机对照试验
该随机对照试验纳入225例HIV/AIDS疑似社区获得性肺炎住院患者,比较头孢曲松联合大环内酯与头孢曲松单药的疗效。主要终点院内死亡率两组无统计学差异(11% vs 15%,HR 1.22,95%CI 0.57-2.59),所有次要终点亦无差异,联合治疗未改善患者结局。
要点
- HIV/AIDS住院CAP患者中,头孢曲松联合大环内酯未降低院内死亡率。
- 14天死亡率、血管活性药需求、机械通气需求等次要终点两组均无差异。
- 不推荐仅因HIV/AIDS状态常规加用大环内酯覆盖非典型病原体。
核心结论
- 在HIV/AIDS住院CAP患者中,头孢曲松联合大环内酯与头孢曲松单药相比未改善患者结局。
研究设计与样本
- 随机对照试验,纳入227例HIV住院疑似CAP成人患者,随机后排除2例,最终分析225例(头孢曲松+安慰剂组112例,头孢曲松+大环内酯组113例),1:1分组(巴西临床试验注册号RBR-8wtq2b)。
主要发现
- 主要终点院内死亡率:头孢曲松+安慰剂组12/112(11%),头孢曲松+大环内酯组17/113(15%),HR 1.22(95%CI 0.57-2.59),无统计学差异。
- 14天死亡率:头孢曲松+安慰剂组5/112(4%),头孢曲松+大环内酯组12/113(11%),RR 2.38(95%CI 0.87-6.53),无统计学差异。
- 血管活性药需求、机械通气需求、临床稳定时间及住院时长等次要终点两组均无差异。
临床怎么用
- 对HIV/AIDS住院CAP患者,经验性治疗可考虑头孢曲松单药,无需常规联合大环内酯。
- 临床决策应结合当地病原体流行病学、患者病情严重程度及个体化评估。
局限性
- 原文摘要未报告盲法、具体给药方案、非典型病原体检出率及亚组分析结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate if treatment with ceftriaxone and a macrolide, improved patient outcome when compared with monotherapy with ceftriaxone, in hospitalized patients with human immunodeficiency virus/acquired immunodeficient syndrome (HIV/AIDS) with community-acquired pneumonia (CAP). METHODS: Adult patients with HIV hospitalized due to suspected CAP were randomized to receive one of two regimens, ceftriaxone plus macrolide or ceftriaxone plus placebo, at a 1:1 proportion (Brazilian Clinical Trials Registry: RBR-8wtq2b). The primary outcome was in-hospital mortality and the secondary outcomes were mortality within 14 days, need for vasoactive drugs, need for mechanical ventilation, time to clinical stability and length of hospitalization. RESULTS: A total of 227 patients were randomized, two were excluded after randomization; 225 patients were analysed (112 receiving ceftriaxone plus placebo and 113 receiving ceftriaxone plus macrolide). The frequency of the primary outcome, in-hospital mortality, was not statistically different between the regimens: 12/112 (11%) patients who received ceftriaxone plus placebo and 17/113 (15%) who received ceftriaxone plus macrolide died during hospitalization (hazard ratio 1.22, 95% CI 0.57-2.59). We did not find differences between the regimens for any of the secondary outcomes, including mortality within 14 days, which occurred in 5/112 (4%) patients with ceftriaxone plus placebo and in 12/113 (11%) patients with ceftriaxone plus macrolide (relative risk 2.38, 95% CI 0.87-6.53). CONCLUSIONS: Among hospitalized patients with HIV/AIDS with CAP, treatment with ceftriaxone and a macrolide did not improve patient outcomes, when compared with ceftriaxone monotherapy.
引用
- Figueiredo-Mello C, Naucler P, Negra MD, et al. Ceftriaxone versus ceftriaxone plus a macrolide for community-acquired pneumonia in hospitalized patients with HIV/AIDS: a randomized controlled trial. Clin Microbiol Infect. 2017. PMID: 28648859. doi:10.1016/j.cmi.2017.06.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。